Drug Absorption Flashcards

1
Q

what is the rate limiting steps for oral absorption?

A
A. Disintegration time and 
    dissolution rate*
B. Gastric emptying and intestinal 
    transit
C. Movement through membranes 
    a) perfusion  or   
    b) permeability limitations
D. First-pass metabolism in the 
    gut/liver
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

what are the characteristics of the intestinal lumen?

A

very thin layer - multiple ways the drug move through reach systemic circulation,.

  • transcellular
  • paracellular
  • transporters
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what is transcellular transport/

A

through the cell

passive diffusion, active transport or facilitated transport.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

what is transcellular transport dependent on?

A

 lipophilicity – more lipophilic more permeable
 molecular size –
 degree of ionisation
 molecular structure – H-donor/acceptor, functional groups
 surface area available – varies along the gut

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

what is paracellular?

A
transport between epithetlial cells
	Mainly via passive diffusion
	Not a dominant process
	Important for polar hydrophilic drugs
	Dependent on: molecular size, size and density of the junctions, surface area
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what are effect of efflux transporters on bioavailbility?

A

P-glycoprotein (P-gp) - located on the apical membrane of enterocytes, biliary canalicular membrane of hepatocytes + other tissues!

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

what is the effect of P-gp on bioavailabilty?

A

P-gp decreases concentration of drugs and metabolites in the enterocytes via active efflux unto the intestinal lumen

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

what is the P-gp and CYP3A4 relationship?

A
  • causes recirculation of the drug
  • increases the exposure to CYP3A4
  • generally leads to lower bioavailabilty
  • inter-indivudual variability in drug absorption and bioavailabilty
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

what are the rate limiting steps in drug absorption?

A

Movement of drug across membrane may be rate limited by either
• Perfusion - membrane is not a barrier so it can pass through very easily. Rapid movement through membrane
• Permeability - barrier is produced through the membrane

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what is perfusion rate limitation?

A

 Membrane offers no effective barrier to drug
 Molecule readily passes across membrane
 small lipophilic molecules (many drugs)
 very small hydrophilic molecules (water)
 Absorption rate varies with blood flow

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

what is permability limited absorption?

A

Molecule has difficulty passing across membrane - poor permeability
 Large polar hydrophilic molecules (most newly developed drugs)
 Absorption insensitive to changes in blood flow
 For acids and bases, ionization is an additional consideration
- unionized form of the drug assumed to be sufficiently lipophilic to cross the membrane.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

what is release or dissolution rate limited absorption?

A

 Modified/controlled release formulations – MR, CR
 Adjusted rate of release from the formulation
 Affects the absorption and plasma concentration-time profile of a drug
 Different dosing interval compared to immediate release formulations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

does the permeability of the intestinal wall membrane change along GIT?

A

 YES! Changes in permeability along GIT will affect rate limitation
 Important for sustained release formulations
 Poorly permeable drugs NOT good candidates for extended release formulations
 Expression of metabolic enzymes also varies
 Rate limitation to begin with is the release of the drug and then after this there is no issues as it is a permeable membrane. But as you move to distal region the poor permeability is the rate limitation there is a shift.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

what are the implication of intestinal first pass/

A

 Can limit the value of the oral route - extensive metabolism in enterocytes (results in low FG )
 Significant contributor to low and variable F of a number of drugs (CYP3A- statins, HIV protease inhibitors; UGT- raloxifene)
 Transporter-metabolism interplay additional factor contributing to low F
 Inhibition of intestinal enzymes and transporters contributes to the extent of drug-drug interactions reported for many drugs
 Absorption site – intestinal lume

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

what are irreverisble inhibirors which can cause a clinical drug-drug or drug-food interaction?

A

 Furanocoumarins present in grapefruit juice are irreversible inhibitors of intestinal CYP3A4
 Standard dose has no effect on hepatic CYP3A4
 Co-administration of grapefruit juice and CYP3A4 substrates (e.g., some statins) can:
 Prevent metabolism and elimination of the ‘victim’ drug
  plasma concentrations of the ‘victim’ drug
 Recommended NOT to be taken with some statins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

what are the effects of grapefruit juice on simvastatin/

A
  • Simvastatin – F<5%, extensive first-pass metabolism (intestine and liver)
  • Grapefruit juice Cmax and AUC of simvastatin
  • Leads to  risk of adverse effects of simvastatin
17
Q

what are examples of drugs with low oral bioavailabilty due to extensive first pass?

A
  • Saquinavir
  • Felodipine
  • Simvastatin
  • Atorvastatin
  • Lovastatin
  • Rifabutin
  • Cyclosporine
  • Tacrolimus
  • Nisoldipine
  • Sildenafil
  • Verapamil
  • Diltiazem
18
Q

what factors affect bioavailabiluty?

A

 Incomplete absorption – F
 Low intestinal permeability of large polar molecules (vancomycin)
 Poor dissolution (sparingly soluble drugs)
 Extensive first-pass metabolism in the intestine and liver - F
 Inhibition of hepatic or intestinal first-pass - F
 Competing reaction – enzymatic (e.g., intestinal P450 and
efflux transporters) or non-enzymatic (complexation)*
 Effect of surgery/disease status of the patient
 gastric bypass – F or F
 coeliac disease, liver cirrhosis (mainly CYP3A substrates

19
Q

what is intramuscular /subcut absorption?

A

 Rate limited step will depend on the characteristics of the drug and the membrane
 Muscle capillary membrane
 Nature of barrier different to the gut wall - membrane is more porous, drugs more readily absorbed via paracellular route
 Generally perfusion rate limited
 Transdermal absorption (patches) – permeability rate limited absorption even for lipophilic compounds

20
Q

what is pulmonary absorption?

A

 Important for inhalers and treatment of respiratory diseases (asthma, chronic obstructive pulmonary disease)
 Rapid access to systemic circulation due to large surface area of lungs
 Avoids first-pass metabolism
 Disadvantage – commonly only 2-10 % aerosol dose deposited in lungs, 90% dose is swallowed!
 Deposition of inhaled particles depends on the particle characteristics, inhaling device and morphology of the respiratory tract